Allowing Greater Access to Safe and Effective Contraception Act

Summary

Requires HHS/FDA to give priority review and waive FDA supplemental application fees for drug-makers seeking to switch routine oral contraceptives to over-the-counter use for people age 18 and older, while keeping prescription-only status for those under 18. Also directs the Government Accountability Office to report to Congress within one year on federal spending over the prior 15 years that supported contraception reimbursement, stocking, provider training, or patient education across a set of federal programs and providers.

• HHS/FDA must prioritize supplemental applications to switch routine oral contraceptives to over-the-counter use for people 18 and older.
• The FDA user fee for qualifying supplemental OTC applications is waived.
• Emergency contraceptives and drugs also approved for induced abortion are excluded from the priority/waiver rule.
• Prescription-only status is explicitly preserved for individuals under 18 even if an OTC approval for adults occurs.
• Priority-review and fee-waiver provisions apply to applications pending at enactment and to those submitted after enactment.
• The GAO must report to Congress within one year on 15 years of federal funding for contraception-related reimbursement, stocking, training, and education.
• The GAO study must quantify funding across Medicare, Medicaid, Indian Health Service, ACA exchanges, FQHCs, title X, TANF, and TRICARE.
• The bill does not appropriate new funds or create new federal entitlement programs; it alters regulatory review and requests a federal funding study.